Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRK1 | P41145 | 5/20 | 0.59 |
| ▸ | HDAC6 | Q9UBN7 | 5/20 | 0.58 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.58 |
| ▸ | HDAC8 | Q9BY41 | 4/20 | 0.58 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.48 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.44 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.44 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.44 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.44 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.44 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.44 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.44 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.44 |
| ▸ | TACR1 | P25103 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 3/20 | 0.41 |
| ▸ | PKM | P14618 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | GHSR | Q92847 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1714279 | 1.00 | OPRK1 (0.59) | OPRK1HDAC6HDAC1HDAC8EPHX2 | |
| SCHEMBL6343378 | 1.00 | OPRK1 (0.59) | OPRK1HDAC6HDAC1HDAC8EPHX2 | |
| SCHEMBL19095468 | 0.89 | OPRK1 (0.57) | OPRK1HDAC6HDAC1HDAC8EPHX2 | |
| SCHEMBL10219026 | 0.89 | OPRK1 (0.57) | OPRK1HDAC6HDAC1HDAC8EPHX2 | |
| SCHEMBL1714131 | 0.89 | OPRK1 (0.57) | OPRK1HDAC6HDAC1HDAC8EPHX2 | |
| SCHEMBL876552 | 0.87 | HDAC6 (0.73) | OPRK1HDAC6HDAC1HDAC8EPHX2 | |
| SCHEMBL8452072 | 0.87 | HDAC6 (0.73) | OPRK1HDAC6HDAC1HDAC8EPHX2 | |
| SCHEMBL877776 | 0.87 | HDAC6 (0.73) | OPRK1HDAC6HDAC1HDAC8EPHX2 | |
| SCHEMBL10219033 | 0.86 | OPRK1 (0.55) | OPRK1HDAC6HDAC1HDAC8EPHX2 | |
| SCHEMBL8154689 | 0.86 | OPRK1 (0.55) | OPRK1HDAC6HDAC1HDAC8EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023125681-A1 | HETEROCYCLIC COMPOUNDS | BEIGENE, LTD. (KY) | 2023-07-06 | — | — | WO | disclosed |
| CN-106590304-A | Cement polymer environmental-friendly exterior wall coating material | 佛山市顺德区数码彩涂料有限公司 | 2017-04-26 | — | — | CN | disclosed |
| CN-106590304-A | Cement polymer environmental-friendly exterior wall coating material | 佛山市顺德区数码彩涂料有限公司 | 2017-04-26 | — | — | CN | disclosed |
| US-8097610-B2 | Derivative having PPAR agonistic activity | SHIONOGI & CO., LTD. (JP) | 2012-01-17 | — | — | US | disclosed |
| US-8097610-B2 | Derivative having PPAR agonistic activity | SHIONOGI & CO., LTD. (JP) | 2012-01-17 | — | — | US | disclosed |
| US-8097610-B2 | Derivative having PPAR agonistic activity | SHIONOGI & CO., LTD. (JP) | 2012-01-17 | — | — | US | disclosed |
| US-20090286974-A1 | Derivative having ppar agonistic activity | SHIONOGI & CO., LTD. (JP) | 2009-11-19 | — | — | US | disclosed |
| US-20090286974-A1 | Derivative having ppar agonistic activity | SHIONOGI & CO., LTD. (JP) | 2009-11-19 | — | — | US | disclosed |
| US-20090286974-A1 | Derivative having ppar agonistic activity | SHIONOGI & CO., LTD. (JP) | 2009-11-19 | — | — | US | disclosed |
| EP-1939189-A1 | DERIVATIVE HAVING PPAR AGONISTIC ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2008-07-02 | — | — | EP | disclosed |
| EP-1939189-A1 | DERIVATIVE HAVING PPAR AGONISTIC ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2008-07-02 | — | — | EP | disclosed |
| US-20050272745-A1 | Novel piperidine and piperazine derivatives | ASTRAZENECA AB | 2005-12-08 | — | — | US | disclosed |
| US-6969713-B2 | Piperidine and piperazine acetamide derivatives | ASTRAZENECA AB (SE) | 2005-11-29 | — | — | US | disclosed |
| US-6967201-B1 | for increasing activation of the 5-HT2C receptor in mammals; treatment of depression, obesity, bulimia, premenstrual syndrome, alcoholism, tobacco abuse, panic disorder | ELI LILLY AND COMPANY (US) | 2005-11-22 | — | — | US | disclosed |
| US-6638936-B1 | Treatment of obesity in mammals, comprising administering to mammal in need of such treatment, treatment of obsessive compulsive disorder in mammals, comprising administering to a mammal treatment of depression in mammals | ELI LILLY AND COMPANY | 2003-10-28 | — | — | US | disclosed |
| EP-1242427-B1 | NOVEL PIPERIDINE AND PIPERAZINE DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS | ASTRAZENECA AB (SE) | 2003-08-13 | — | — | EP | disclosed |
| EP-1204654-B1 | BENZOFURYLPIPERAZINES: 5-HT2C SEROTONIN RECEPTOR AGONISTS | LILLY CO ELI (US) | 2003-07-23 | — | — | EP | disclosed |
| EP-1204658-B1 | BENZOFURYLPIPERAZINE SEROTONIN AGONISTS | LILLY CO ELI (US) | 2003-05-07 | — | — | EP | disclosed |
| US-20030013721-A1 | Novel piperidine and piperazine derivatives | ASTRAZENECA AB (SE) | 2003-01-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050272745-A1 | Novel piperidine and piperazine derivatives | CYP3A5, IL5, ABCC5 | OPRK1 366/4885HDAC6 87/4885HDAC1 613/4885 |
| US-20030013721-A1 | Novel piperidine and piperazine derivatives | IL5, VIP, EP300 | OPRK1 148/4885HDAC6 36/4885HDAC1 300/4885 |
| US-20090286974-A1 | Derivative having ppar agonistic activity | PPARD, PPARA, PPARG | OPRK1 301/4885HDAC6 724/4885HDAC1 288/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.